Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLMC 2020 | Oral therapies in the future of AML treatment

Sangmin Lee • 21 Oct 2020
LLMC 2020
Acute Myeloid Leukemia Azacitidine Venetoclax
QUAZAR AML-001

Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, discusses the future of acute myeloid leukemia (AML) treatment, highlighting the approval of oral azacitidine as a maintenance therapy for patients undergoing induction chemotherapy who are not eligible for curative therapy as a result of the Phase III QUAZAR AML-001 trial (NCT01757535). Dr Lee also discusses how future research will focus on developing oral hypomethylating agents to be used in combination with oral venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

Consultancy: AstraZeneca, BMS, Jazz, Roche Diagnostics
DSMB membership: Helsinn

More from Sangmin Lee

Updates on the treatment of MDS
1:45
Updates on the treatment of MDS
Sangmin Lee • 20 Oct 2021
Challenges in treating AML
1:07
Challenges in treating AML
Sangmin Lee • 20 Oct 2021
Rare blood diseases at LLM 2021
1:13
Rare blood diseases at LLM 2021
Sangmin Lee • 20 Oct 2021
Updated overall survival data on eltanexor for HMA-refractory MDS
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals